サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1794614

末梢神経障害治療の世界市場

Peripheral Neuropathy Treatment

出版日
ページ情報
英文 273 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.79円
末梢神経障害治療の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 273 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

末梢神経障害治療の世界市場は2030年までに22億米ドルに達する

2024年に19億米ドルと推定される末梢神経障害治療の世界市場は、分析期間2024-2030年にCAGR 2.8%で成長し、2030年には22億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである薬物療法は、CAGR 2.2%を記録し、分析期間終了時には13億米ドルに達すると予測されます。非薬物療法分野の成長率は、分析期間中CAGR 3.9％と推定されます。

米国市場は5億1,850万米ドルと推定、中国はCAGR 5.2％で成長予測

米国の末梢神経障害治療市場は、2024年には5億1,850万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.2%として、2030年までに4億3,410万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.1%と2.1%と予測されています。欧州では、ドイツがCAGR 1.6%で成長すると予測されています。

世界の末梢神経障害治療市場- 主要動向と促進要因のまとめ

末梢神経障害治療が医療システム全体の臨床的優先度を高めている理由とは？

末梢神経障害は、末梢神経の損傷によって生じる複雑で、しばしば進行性の病態であり、痛み、しびれ、しびれ、筋力低下などの症状を引き起こします。原因としては、糖尿病、化学療法、自己免疫疾患、感染症、ビタミン欠乏症などが挙げられます。糖尿病や慢性疾患の罹患率が世界的に上昇する中、末梢神経障害は神経学や疼痛管理における重要な関心事として浮上しています。

治療アプローチは一般的に対症療法であり、疼痛緩和、機能回復、疾患の進行抑制に重点を置いています。万能の治療法が存在しない以上、臨床的な焦点は依然として多剤併用療法の最適化にあります。これには、薬理学的管理、身体的リハビリテーション、生活習慣の改善、基礎疾患に対する標的介入などが含まれます。

薬理学的治療と非薬理学的治療はどのように進化しているか？

薬理学的治療には、プレガバリンやガバペンチンなどの抗けいれん薬、デュロキセチンなどの抗うつ薬、カプサイシンパッチやリドカインなどの外用薬などがあります。これらは神経障害性疼痛の管理を目的としているが、反応には個人差があることが多いです。特に糖尿病性神経障害や化学療法による神経障害では、神経機能を再生させたり、変性に歯止めをかけたりすることができる疾患修飾治療を特定するための努力が続けられています。

理学療法、経皮的電気神経刺激（TENS）、鍼治療などの非薬理学的アプローチは、慢性疼痛のコントロールや感覚改善のために支持を集めています。代謝性神経障害では、特にα-リポ酸やビタミンB12を含む栄養補助食品が用いられます。長期的な障害を管理し、生活の質を向上させるために、薬物療法と支持療法を組み合わせた、患者に合わせたケアパスがますます増えています。

治療需要はどこで増加し、どのような層が最も影響を受けるか？

治療需要が最も高いのは、糖尿病患者、がん生存者、高齢者層です。糖尿病性神経障害は依然として主要なサブタイプであり、高所得国と中所得国の両方で有病率が増加しています。腫瘍クリニックでは、化学療法誘発性末梢神経障害（CIPN）の症例が増加しており、これは患者の回復や生活の質に影響を及ぼす用量制限性の副作用です。

プライマリ・ケアや神経内科では、早期発見と統合治療に対する需要が高まっています。農村部や診断が不十分な地域では、診断が遅れ、症状が管理されないリスクが残っています。包括的な治療サービスを提供する上で、病院、専門のペインクリニック、在宅ケアプロバイダーが重要な役割を担っています。公衆衛生キャンペーンや医療従事者への教育活動も、早期発見・早期紹介に貢献しています。

末梢神経障害治療市場の成長はいくつかの要因によって牽引される...

末梢神経障害治療市場の成長は、糖尿病やがんに関連した神経障害の有病率の上昇、慢性疼痛管理への注目の高まり、薬理療法の幅広い利用可能性などの要因によって牽引されます。局所製剤の進歩、神経障害性疼痛治療薬の忍容性の向上、個別化された治療計画が臨床成果を高めています。

非オピオイド性疼痛治療薬や新規の神経保護化合物の開発により、治療の選択肢が広がっています。患者や臨床医の間で認識が高まり、症状モニタリングや遠隔疼痛管理のためのデジタルツールが統合されたことで、長期的なケアモデルが支持されています。ヘルスケアシステムが慢性疾患管理インフラに投資する中、効果的なマルチモーダル神経障害治療に対する需要は世界的に拡大し続けています。

セグメント

治療法（薬物療法、非薬物療法）、タイプ（糖尿病性末梢神経障害、化学療法誘発性末梢神経障害、その他のタイプ）

調査対象企業の例

  • Acorda Therapeutics
  • Arbor Pharmaceuticals
  • Biogen Inc.
  • Biohaven Pharmaceuticals
  • Boehringer Ingelheim
  • Cipla Limited
  • Daiichi Sankyo
  • Eli Lilly and Company
  • GlaxoSmithKline（GSK）
  • Grunenthal GmbH
  • Johnson & Johnson
  • Lupin Limited
  • MediciNova Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regenacy Pharmaceuticals
  • Sorrento Therapeutics
  • Teva Pharmaceutical Industries
  • Vertex Pharmaceuticals

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37706

Global Peripheral Neuropathy Treatment Market to Reach US$2.2 Billion by 2030

The global market for Peripheral Neuropathy Treatment estimated at US$1.9 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2024-2030. Pharmacological Therapy, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Non-Pharmacological Therapy segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$518.5 Million While China is Forecast to Grow at 5.2% CAGR

The Peripheral Neuropathy Treatment market in the U.S. is estimated at US$518.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$434.1 Million by the year 2030 trailing a CAGR of 5.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Peripheral Neuropathy Treatment Market - Key Trends & Drivers Summarized

Why Is Peripheral Neuropathy Treatment Gaining Clinical Priority Across Health Systems?

Peripheral neuropathy is a complex, often progressive condition resulting from damage to peripheral nerves, leading to symptoms such as pain, numbness, tingling, and muscle weakness. Causes include diabetes, chemotherapy, autoimmune disorders, infections, and vitamin deficiencies. As the incidence of diabetes and chronic diseases rises globally, peripheral neuropathy is emerging as a significant concern in neurology and pain management.

Treatment approaches are typically symptomatic, focusing on pain relief, functional restoration, and slowing disease progression. Given the absence of a universal cure, the clinical focus remains on optimizing multimodal therapies. This includes pharmacological management, physical rehabilitation, lifestyle modification, and targeted interventions for underlying conditions.

How Are Pharmacological and Non-Pharmacological Therapies Evolving?

Pharmacological treatment includes anticonvulsants such as pregabalin and gabapentin, antidepressants like duloxetine, and topical agents including capsaicin patches and lidocaine. These aim to manage neuropathic pain, although individual response often varies. Efforts are ongoing to identify disease-modifying treatments that can regenerate nerve function or halt degeneration, particularly in diabetic and chemotherapy-induced neuropathy.

Non-pharmacological approaches such as physical therapy, transcutaneous electrical nerve stimulation (TENS), and acupuncture are gaining traction for chronic pain control and sensory improvement. Nutritional supplements, especially those containing alpha-lipoic acid and vitamin B12, are used in metabolic neuropathies. Patient-tailored care pathways are increasingly combining pharmacologic and supportive therapies to manage long-term disability and improve quality of life.

Where Is Treatment Demand Rising and Which Demographics Are Most Affected?

The highest treatment demand is among individuals with diabetes, cancer survivors, and elderly populations. Diabetic neuropathy remains the leading subtype, with growing prevalence in both high- and middle-income countries. Oncology clinics are seeing increased cases of chemotherapy-induced peripheral neuropathy (CIPN), a dose-limiting side effect impacting patient recovery and quality of life.

In primary care and neurology practices, demand for early detection and integrated treatment is growing. Rural and underdiagnosed populations remain at risk of late-stage diagnosis and unmanaged symptoms. Hospitals, specialty pain clinics, and home care providers are key players in delivering comprehensive treatment services. Public health campaigns and provider education initiatives are also contributing to earlier recognition and referral.

Growth in the Peripheral Neuropathy Treatment market is driven by several factors…

Growth in the peripheral neuropathy treatment market is driven by factors such as rising prevalence of diabetes and cancer-related neuropathy, increasing focus on chronic pain management, and wider availability of pharmacologic therapies. Advances in topical formulations, improved tolerability of neuropathic pain drugs, and personalized treatment plans are enhancing clinical outcomes.

Development of non-opioid pain therapies and novel neuroprotective compounds is expanding therapeutic options. Greater awareness among patients and clinicians, along with integration of digital tools for symptom monitoring and remote pain management, is supporting long-term care models. As healthcare systems invest in chronic disease management infrastructure, demand for effective, multimodal neuropathy treatment continues to expand globally.

SCOPE OF STUDY:

The report analyzes the Peripheral Neuropathy Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Pharmacological Therapy, Non-Pharmacological Therapy); Type (Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy, Other Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • Acorda Therapeutics
  • Arbor Pharmaceuticals
  • Biogen Inc.
  • Biohaven Pharmaceuticals
  • Boehringer Ingelheim
  • Cipla Limited
  • Daiichi Sankyo
  • Eli Lilly and Company
  • GlaxoSmithKline (GSK)
  • Grunenthal GmbH
  • Johnson & Johnson
  • Lupin Limited
  • MediciNova Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regenacy Pharmaceuticals
  • Sorrento Therapeutics
  • Teva Pharmaceutical Industries
  • Vertex Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Peripheral Neuropathy Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Diabetic Population and Chemotherapy-Induced Neuropathy Cases Spur Demand for Peripheral Neuropathy Treatment
    • Growth in Awareness and Early Screening Initiatives Throws the Spotlight on Timely Multimodal Interventions
    • OEM Innovation in Neuromodulation Devices and Wearable Stimulators Enhances Non-Pharmacological Management Options
    • Expansion of Topical and Oral Drug Formulations Strengthens Accessibility for Diverse Patient Profiles
    • Increased Research on Nerve Regeneration and Neuroprotective Agents Fuels Development of Disease-Modifying Therapies
    • Surge in Aging Population With Chronic Pain and Comorbidities Expands the Need for Safe, Long-Term Management Strategies
    • OEM Focus on Drug Delivery Systems Targeting Peripheral Nerve Pathways Enhances Pain Relief Efficacy
    • Adoption of Cognitive Behavioral Therapy and Tele-Rehabilitation Expands Holistic Management Approach
    • Rising Demand for Personalized Medicine Supports Pharmacogenomic Profiling for Tailored Treatment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Peripheral Neuropathy Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Peripheral Neuropathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Peripheral Neuropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pharmacological Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pharmacological Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Pharmacological Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Pharmacological Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Pharmacological Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Non-Pharmacological Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Diabetic Peripheral Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Diabetic Peripheral Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Diabetic Peripheral Neuropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Chemotherapy-Induced Peripheral Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Chemotherapy-Induced Peripheral Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Chemotherapy-Induced Peripheral Neuropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • JAPAN
    • Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • CHINA
    • Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • EUROPE
    • Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Peripheral Neuropathy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Peripheral Neuropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • FRANCE
    • Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • GERMANY
    • Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Peripheral Neuropathy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Peripheral Neuropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • INDIA
    • Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Peripheral Neuropathy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Peripheral Neuropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Peripheral Neuropathy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Peripheral Neuropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
  • AFRICA
    • Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030

IV. COMPETITION